Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Anal Cancer: Prevention & Risk Reduction: HPV Vaccination, Smoking Cessation, High-Resolution Anoscopy Screening, and Barrier Protection

A preventive oncology reference on the 9-valent HPV vaccine, barrier protection, smoking cessation, targeted anal cytology and high-resolution anoscopy, treating high-grade lesions, and the symptoms never to ignore.

Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026

Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.

What we found that needs correcting

  • This brief is accurate and covers the right ground. Its framing is correct and matters: anal cancer develops through defined precancerous stages, which makes it one of the cancers that can be prevented rather than only treated. The notes below are one major addition, some specifics on who and when, and a point of proportion on condoms.
  • The ANCHOR trial should be named, because it is the reason screening recommendations changed. It enrolled people with HIV aged 35 and over who had high-grade squamous intraepithelial lesions and randomized them to treatment or monitoring. It was stopped early in 2022 because treating the lesions reduced progression to anal cancer by about 57 percent. Before that, screening rested on reasoning by analogy with cervical cancer. The brief states the conclusion without the evidence that now supports it, and the evidence is recent enough that most clinicians and nearly all patients have not heard of it.
  • Who to screen could be specific about age. Guidelines recommend starting screening at 35 for men who have sex with men and transgender women with HIV, and at 45 for other people with HIV. Solid organ transplant recipients and people with a history of cervical, vulvar or vaginal high-grade lesions are also considered. The brief lists the groups correctly and omits the ages, which is the part someone reading it would act on.
  • The practical bottleneck should be named. Trained high-resolution anoscopy providers are scarce, and cytology without access to HRA has limited value, because an abnormal result then has nowhere to go. Anyone offered anal cytology should ask where HRA is done if the result comes back abnormal.
  • Digital anal rectal examination deserves a place in the brief. A gloved finger examination detects masses that cytology can miss, takes seconds, and is recommended annually in high-risk groups even where cytology and HRA are unavailable. It is the floor, and in many settings it is all that is on offer.
  • Condoms reduce HPV transmission substantially and do not eliminate it, because HPV lives on skin that a condom does not cover. Presenting barrier protection without that qualification overstates what it does, particularly for an infection this common.
  • Two additions on the vaccine: it prevents new infection and does not treat or clear existing infection, and vaccination does not remove the need for screening in high-risk groups. People in the catch-up and shared decision-making age ranges frequently assume both of the opposite.
  • Risk factors beyond the three covered are worth listing, because they define who should be screened: HIV infection itself, which is the strongest; immunosuppression after solid organ transplant; a history of HPV-related disease elsewhere, including cervical and vulvar high-grade lesions; and a history of receptive anal intercourse. Incidence also rises with age, with most diagnoses after 50.
  • One framing point worth adding, because it affects whether people seek help: nobody gives themselves anal cancer. HPV infection is close to universal, most people clear it, and persistent infection is largely a matter of immune luck. The stigma around this cancer measurably delays presentation.
  • Everything else in the brief is accurate: over 90 percent of anal cancers linked to high-risk HPV and predominantly HPV 16; rising incidence; the 9-valent vaccine covering HPV 16 and 18 with routine vaccination at 11 to 12, catch-up through 26 and shared decision-making for 27 to 45; smoking impairing immune clearance of HPV and synergizing with viral oncogenes; anal cytology followed by high-resolution anoscopy in high-risk groups; treating AIN 2/3 and HSIL by ablation or excision to prevent invasive cancer; and the list of symptoms that should never be ignored.

Download the PDF

All source documents